Response to Javaheri et al., “Topical estrogens: Use in hair loss and additional safety concerns for consideration” - 19/05/26
Doi : 10.1016/j.jaad.2026.01.093
Samantha Kalner, BS a, Rachel Hanan, BS b, Eliana Farkas, BA b, Isabella Nehorayan, BS b, Shoshana Marmon, MD, PhD b, c, ⁎ 
a Norton College of Medicine, SUNY Upstate Medical University, Syracuse, New York
b School of Medicine, New York Medical College, Valhalla, New York
c NYC Health + Hospitals/South Brooklyn Health, Brooklyn, New York
∗ Correspondence to: Shoshana Marmon, MD, PhD, Department of Medicine, NYC Health + Hospitals/South Brooklyn Health, Ruth Bader Ginsburg Hospital, 2601 Ocean Pkwy, Brooklyn, NY 11235 Department of Medicine NYC Health + Hospitals/South Brooklyn Health Ruth Bader Ginsburg Hospital 2601 Ocean Pkwy Brooklyn NY 11235
Key words : estradiol, estrogen, female pattern hair loss, FFA, FPHL, frontal fibrosing alopecia, hair loss, menopausal hormone therapy, menopause, MHT, perimenopause, telogen effluvium
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| IRB approval status: Exempt. |
© 2026
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 94 - N° 6
P. e443 - juin 2026 Retour au numéro
Article précédent
- Topical estrogens for skin aging: Use in hair loss and additional safety concerns for consideration
- Elika D. Javaheri, Rewan M. Abdelwahab, Sindhuja Sominidi-Damodaran
- Comments on Akaike et al, “Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management”
- Bi-Yu Gao, Shiuan-Chih Chen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?